Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Page 1
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Bug G, Labopin M, Niittyvuopio R, Stelljes M, Reinhardt HC, Hilgendorf I, Kröger N, Kaare A, Bethge W, Schäfer-Eckart K, Verbeek M, Mielke S, Carlson K, Bazarbachi A, Spyridonidis A, Savani BN, Nagler A, Mohty M. Bug G, et al. Among authors: savani bn. Bone Marrow Transplant. 2023 Jun;58(6):710-716. doi: 10.1038/s41409-023-01965-x. Epub 2023 Mar 31. Bone Marrow Transplant. 2023. PMID: 37002412 Free PMC article.
American Society for Transplantation and Cellular Therapy Return to Work Guidance Committee Recommendations for Health Care Providers Who Take Care of Hematopoietic Cell Transplantation Patients.
Salit RB, Schoeppner K, De Biase C, Mohammed J, Gonzales AL, Hashmi SK, Gea-Banacloche J, Savani BN, Carpenter PA, Syrjala KL. Salit RB, et al. Among authors: savani bn. Transplant Cell Ther. 2022 Dec;28(12):822-828. doi: 10.1016/j.jtct.2022.09.017. Epub 2022 Sep 30. Transplant Cell Ther. 2022. PMID: 36184059 Free article.
Hematopoietic cell transplantation (HCT) health care providers report a desire to improve long-term outcomes and quality of life for their patients. One of the items frequently cited by patients in terms of transitioning from being a patient back to pre-HCT life is return …
Hematopoietic cell transplantation (HCT) health care providers report a desire to improve long-term outcomes and quality of life for …
Irradiation-free, T-cell replete haploidentical transplant for Fanconi anaemia, weighing the benefits.
Connelly JA, Savani BN. Connelly JA, et al. Among authors: savani bn. Br J Haematol. 2022 Dec;199(5):639-641. doi: 10.1111/bjh.18446. Epub 2022 Sep 19. Br J Haematol. 2022. PMID: 36121005
The report by Xu et al. suggests that excellent engraftment and short-term survival can be achieved in FA patients without irradiation, but their retrospective cohort was plagued by a high rate of severe GVHD. ...
The report by Xu et al. suggests that excellent engraftment and short-term survival can be achieved in FA patients without irradiatio …
New Indications and platforms for CAR-T therapy in lymphomas beyond DLBCL.
Iqbal M, Savani BN, Hamadani M. Iqbal M, et al. Among authors: savani bn. EJHaem. 2022 Jan;3(Suppl 1):11-23. doi: 10.1002/jha2.323. Epub 2021 Nov 23. EJHaem. 2022. PMID: 34988550 Free PMC article.
CD19 directed chimeric antigen receptor T-cell therapy (CAR-T) represents a significant advancement for patients with relapsed/refractory large B-cell lymphoma (LBCL). Long term follow-up confirms durable remissions in nearly half of the patients, a population which was pr …
CD19 directed chimeric antigen receptor T-cell therapy (CAR-T) represents a significant advancement for patients with relapsed/refractory la …
How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation.
Fuji S, Byrne M, Nagler A, Mohty M, Savani BN. Fuji S, et al. Among authors: savani bn. Bone Marrow Transplant. 2021 Jun;56(6):1248-1256. doi: 10.1038/s41409-020-01205-6. Epub 2021 Jan 29. Bone Marrow Transplant. 2021. PMID: 33514922 Review.
Although it is well-known that usage of systemic GC is associated with various side effects, the short- and long-term effects of GCs in the HCT setting are not well-characterized due to limited published data. ...
Although it is well-known that usage of systemic GC is associated with various side effects, the short- and long-term effects of GCs …
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.
Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W. Zhou Z, et al. Among authors: savani bn. Blood Adv. 2020 Jul 14;4(13):3180-3190. doi: 10.1182/bloodadvances.2019001266. Blood Adv. 2020. PMID: 32663298 Free PMC article.

NRM was significantly increased in the FM group during the first 3 months of posttransplant (HR = 3.85, P < .001). Long-term relapse was lower with FM (HR = 0.65, P < .001). Analysis restricted to patients with CR showed comparable results. In conclusion, compared wi

…

NRM was significantly increased in the FM group during the first 3 months of posttransplant (HR = 3.85, P < .001). Long-term relap

…
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases.
Kahn JM, Brazauskas R, Tecca HR, Bo-Subait S, Buchbinder D, Battiwala M, Flowers MED, Savani BN, Phelan R, Broglie L, Abraham AA, Keating AK, Daly A, Wirk B, George B, Alter BP, Ustun C, Freytes CO, Beitinjaneh AM, Duncan C, Copelan E, Hildebrandt GC, Murthy HS, Lazarus HM, Auletta JJ, Myers KC, Williams KM, Page KM, Vrooman LM, Norkin M, Byrne M, Diaz MA, Kamani N, Bhatt NS, Rezvani A, Farhadfar N, Mehta PA, Hematti P, Shaw PJ, Kamble RT, Schears R, Olsson RF, Hayashi RJ, Gale RP, Mayo SJ, Chhabra S, Rotz SJ, Badawy SM, Ganguly S, Pavletic S, Nishihori T, Prestidge T, Agrawal V, Hogan WJ, Inamoto Y, Shaw BE, Satwani P. Kahn JM, et al. Among authors: savani bn. Blood Adv. 2020 May 12;4(9):2084-2094. doi: 10.1182/bloodadvances.2019000839. Blood Adv. 2020. PMID: 32396620 Free PMC article.
Despite a low number of SNs, patients had an 11-fold increased SN risk (SIR, 11; 95% CI, 8.9-13.9) compared with the general population. We report excellent long-term survival and low SN incidence in an international cohort of children undergoing HCT for NMDs. The risk of …
Despite a low number of SNs, patients had an 11-fold increased SN risk (SIR, 11; 95% CI, 8.9-13.9) compared with the general population. We …
Survival following allogeneic transplant in patients with myelofibrosis.
Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Luber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W. Gowin K, et al. Among authors: savani bn. Blood Adv. 2020 May 12;4(9):1965-1973. doi: 10.1182/bloodadvances.2019001084. Blood Adv. 2020. PMID: 32384540 Free PMC article.

Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P < .0001; DIPSS-Int-2 and higher: HR, 2.55, P < .0001). In conclusion, long-term OS advantage wi

…
Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT v …
Follow-up issues in survivors of hematologic malignancies - Current stance and future perspectives.
Muhsen IN, Bar M, Savani BN, Estey EH, Hashmi SK. Muhsen IN, et al. Among authors: savani bn. Blood Rev. 2020 Nov;44:100674. doi: 10.1016/j.blre.2020.100674. Epub 2020 Feb 26. Blood Rev. 2020. PMID: 32199685
Cancer care advances have led to increased numbers of cancer survivors and to improved understanding of late effects of cancers and their therapies and survivorship issues. Long-term follow-up of cancer patients is crucial in preventing and managing many of the late effect …
Cancer care advances have led to increased numbers of cancer survivors and to improved understanding of late effects of cancers and their th …
86 results